Zopiclone

From PsychonautWiki
Jump to: navigation, search
Zopiclone
The skeletal formula of zopiclone
Zopiclone1.png
Zopiclone ball-and-stick.png
Chemical Nomenclature
Common names Zimovane, Imovane
Substitutive name Zopiclone
Systematic name (RS)-6-(5-chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate
Class Membership
Psychoactive class Depressant
Chemical class Cyclopyrrolone
Routes of Administration



Oral
Dosage
WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.
DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation.
This dosage and duration information has been sourced from TripSit
Bioavailability 52-59%
Threshold 2 - 3.5 mg
Light 3.5 - 5 mg
Common 5 - 7.5 mg
Strong 7.5 - 15 mg
Heavy 15 - 22 mg +
Duration
Total 3.5 - 9 hours
Onset 10 - 30 minutes









Summary sheet: Zopiclone

Zopiclone (brand names Zimovane and Imovane) is a non-benzodiazepine hypnotic agent used in the treatment of insomnia. It is a cyclopyrrolone, which increases the normal transmission of the neurotransmitter GABA in the central nervous system, similarly, yet differently, to the mechanism of benzodiazepines. As zopiclone is sedating, it is marketed as a sleeping pill.

Zopiclone is known colloquially as a "Z-drug". Other Z-drugs include zaleplon (Sonata) and zolpidem (Ambien and AmbienCR). They were initially thought to be less addictive and/or habit-forming than benzodiazepines. However, this appraisal has shifted somewhat in the last few years as cases of addiction and habituation have been presented. Zopiclone is recommended to be taken on a short-term basis, usually a week or less.[1] Daily or continuous use of the drug is not usually advised.[2]

Chemistry

Zopiclone is a hypnotic nonbenzodiazepine drug of the cyclopyrrolone class. Zopiclone and its closely related dextrorotatory stereoisomer eszopiclone (Lunesta) are the most available cyclopyrrolone drugs. This class of drugs is named for having a pyrrolone constituent, a five-membered ring with a nitrogen constituent (pyrrole) and a ketone group (-one).

The ketone group found in zopiclone is located at R5 of the pyrrolone ring. Zopiclone contains four nitrogenous rings including pyrrolone. Fused to the pyrrolone core is a pyrazine ring, a six-membered aromatic ring with two nitrogen substituents. The two rings are fused at R3 and R4. This bicylic core is called a pyrollopyrazine. Bound to the nitrogen group of the pyrrolone at R6 is a substituted pyridine ring. Pyridine is six-membered unsaturated ring with one nitrogen group. The pyridine ring of zopiclone is substituted at R5 with a chlorine group.

The final ring of zopiclone is a piperazine ring. Piperazine is a six-membered saturated ring with two nitrogen constituents; in this case, it is substituted at R4 with a methyl group. This piperazine ring is connected to the pyrrolone core of zopiclone at R7 through a carboxylate group.

Pharmacology

Zopiclone, although molecularly different from benzodiazepines, shares an almost identical pharmacological profile as them. Its mechanism of action works by binding to the same site as benzodiazepines and acts as a full agonist, which in turn positively modulates benzodiazepine-sensitive GABAA receptors and enhances GABA binding at the GABAA receptors to produce zopiclone's pharmacological properties. Since GABA functions as the brain's predominant inhibitory neurotransmitter, this activation of receptors results in the sedative and anxiolytic effects of zopiclone.

Subjective effects

The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. The listed effects will rarely (if ever) occur all at once, but heavier dosages will increase the chances and are more likely to induce a full range of effects.

In comparison to other compounds of a similar nature such as benzodiazepines, this compound presents significantly less anxiety suppression or disinhibition and instead focuses primarily on sedation.

Physical effects

  • Sedation - In terms of energy level alterations, zopiclone is extremely sedating and often results in an overwhelmingly lethargic state. At higher levels, this causes users to suddenly feel as if they are extremely sleep deprived and have not slept for days, forcing them to sit down and generally feel as if they are constantly on the verge of passing out instead of engaging in physical activities. This sense of sleep deprivation increases proportional to dosage and eventually becomes powerful enough to force a person into complete unconsciousness.
  • Respiratory depression
  • Muscle relaxation
  • Dizziness
  • Motor control loss

Cognitive effects

The cognitive effects of zopiclone can be broken down into several components which progressively intensify proportional to dosage. The general head space of zopiclone is described by many as one of intense sedation and decreased inhibition. It contains a large number of typical depressants cognitive effects.

The most prominent of these cognitive effects generally include:

Toxicity and harm potential

Zopiclone likely has a low toxicity relative to dose. However, it is potentially lethal when mixed with depressants like benzodiazepines, alcohol or opioids.

It is strongly recommended that one use harm reduction practices when using this drug.

Lethal dosage

Zopiclone is capable of resulting in death at appropriately high doses and is sometimes used as a method of suicide.[3][4] It has a similar fatality index as benzodiazepine drugs, apart from temazepam, which is particularly toxic in overdose.[5][6][7][8][9]

An overdose of zopiclone may present with excessive sedation and depressed respiratory function that may progress to coma and possibly death.[10] Zopiclone combined with alcohol, opiates, or other central nervous system depressants may be even more likely to lead to fatal overdoses. Zopiclone overdoses can be treated with the benzodiazepine receptor antagonist flumazenil, which displaces zopiclone from its binding site on the benzodiazepine receptor, thereby rapidly reversing its effects.[11][12] Serious effects on the heart may also occur from a zopiclone overdose[13][14] when combined with piperazine.[15]

Tolerance and addiction potential

Zopiclone is extremely physically and psychologically addictive. This compound may have an even greater addictive potential than benzodiazepines and has been described as a "benzodiazepine in disguise".[16][17][18]

Tolerance will develop to the sedative-hypnotic effects within a couple of weeks of daily use. After cessation, the tolerance returns to baseline in 7 - 14 days. Withdrawal symptoms or rebound symptoms may occur after ceasing treatment abruptly following a few weeks or longer of steady dosing, and may necessitate a gradual dose reduction.

Physical dependence, recreational abuse and withdrawal syndromes similar to those seen in benzodiazepine withdrawal are frequently encountered.[19] Due to the risk of tolerance and physical dependence, zopiclone is only recommended for short-term relief of insomnia, or alternatively, long-term infrequent use.[20] Abrupt withdrawal, particularly with prolonged and high doses, can (in severe cases) cause seizures and delirium.[21][22]Withdrawal symptoms included anxiety, tachycardia, tremors, sweats, flushes, palpitations, derealisation, and further insomnia.[23] Suspected withdrawal convulsions during detoxification from zopiclone have been reported, but the individual was a high-dose zopiclone misuser.[24]

If zopiclone has been taken for more than a few weeks, then the medication should be gradually reduced or preferably crossed over to an equivalent dose of diazepam (Valium) which has a much longer half-life, making withdrawal easier. One should then gradually taper the dose over a period of several months to avoid extremely severe and unpleasant withdrawal symptoms which can last up to two years after withdrawal if the withdrawal is done too abruptly.[25][26][27]

Zopiclone presents cross-tolerance with all benzodiazepines, meaning that after its consumption benzodiazepines and most other GABAgenic depressants will have a reduced effect.[28] Alcohol has cross tolerance with GABAA receptor positive modulators such as the benzodiazepines and the nonbenzodiazepine drugs. For this reason, alcoholics or recovering alcoholics may be at increased risk of physical dependence on zopiclone. It should therefore be avoided in those with a history of alcoholism or drug misuse.

Dangerous interactions

Although many drugs are safe on their own, they can become dangerous and even life-threatening when combined with other substances. The list below contains some common potentially dangerous combinations, but may not include all of them. Certain combinations may be safe in low doses of each but still increase the potential risk of death. Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

Legal issues

  • U.S.: On April 4, 2005, the U.S. Drug Enforcement Administration listed zopiclone under Schedule IV due to evidence that the drug has addictive properties similar to benzodiazepines.
  • U.K.: The drug is prescription only.
  • Australia: Zopiclone is prescription only.

See also

External links

References

  1. http://www.nice.org.uk/nicemedia/pdf/TA077publicinfoenglish.pdf
  2. Effects of zopiclone and temazepam on sleep, behaviour and mood during the day (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/2744064
  3. Zopiclone fatality in a hospitalized patient (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/9068198
  4. Detection and quantification of the hypnotic zopiclone, connected with an uncommon case of drowning (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/8939015
  5. Relative toxicity of benzodiazepines in overdose (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/9068198
  6. Buckley NA, Dawson AH, Whyte IM, McManus P, Ferguson N.Correlations between prescriptions and drugs taken in self-poisoning: Implications for prescribers and drug regulation.Med J Aust (in press)
  7. Relative toxicity of benzodiazepines in overdose
  8. Analysis of zopiclone (Imovane) in postmortem specimens by GC-MS and HPLC with diode-array detection (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/8837952
  9. An autopsy case of poisoning by neuropsychopharmaceuticals including zopiclone (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/9893443
  10. Two cases of fatal zopiclone overdose (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/8868406
  11. Zopiclone overdose responsive to flumazenil (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/16235515
  12. Zopiclone poisoning: tissue distribution and potential for postmortem diffusion (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/8039775
  13. First-degree heart block caused by voluntary zopiclone poisoning (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/2353332
  14. Auriculo-ventricular block during voluntary poisoning with zopiclone (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/2814922
  15. Dart, Richard C. (2003). Medical Toxicology. p. 889. ISBN 978-0-7817-2845-4.
  16. Adverse effects of zopiclone (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/9656789
  17. Imovane--a benzodiazepine in disguise (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/8321452
  18. The role of liquid chromatography-tandem mass spectrometry (LC-MS/MS) to test blood and urine samples for the toxicological investigation of drug-facilitated crimes (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/18367985
  19. Evaluation of zopiclone physical dependence liability in normal volunteers (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/6669632
  20. An assessment of short-acting hypnotics (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/8573298
  21. Hypnotic dependence: zolpidem and zopiclone too (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/11503851
  22. Zopiclone withdrawal: an unusual cause of delirium in the elderly (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/16107464
  23. Physical dependence on zopiclone: case reports (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/9462317
  24. Misuse of zopiclone and convulsions during withdrawal (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/1754610
  25. http://www.sanofi.ca/products/en/imovane.pdf
  26. A case of primary zopiclone dependence (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/11450624
  27. BENZODIAZEPINES: HOW THEY WORK AND HOW TO WITHDRAW | http://www.benzo.org.uk/manual/
  28. Zopiclone and triazolam in insomnia associated with generalized anxiety disorder: a placebo-controlled evaluation of efficacy and daytime anxiety (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/7862917